First clinical implementation of RayStation at MGH

RaySearch Laboratories AB announces that the first cancer patient has been treated using a treatment plan created with RaySearch's treatment planning system RayStation®. The treatment was carried out at the Massachusetts General Hospital Radiation Oncology Department. The patient is being treated for a brain tumor using Intensity Modulated Radiation Therapy (IMRT) and the treatments are being delivered on an Elekta linear accelerator.

The plan was developed using a unique software solution for IMRT called multi-criteria optimization (MCO). This highly intuitive tool is integrated in RayStation® and lets the clinician evaluate the impact of changing different treatment priorities in real-time, which has a large potential to speed up the time-consuming treatment planning optimization process.

"We are pleased that we have now treated the initial patient with multi-criteria optimization for IMRT," says David Craft, PhD, of Radiation Oncology Department at Massachusetts General Hospital. "Our ultimate goal is to deliver the radiation dose precisely to the intended target while sparing as much healthy brain as possible. Multi-criteria optimization helps us control the conformality of the dose to the specific treatment location. We are looking forward to applying this technology to other disease sites."

"We are excited that the first clinical implementation of RayStation® was done by the team at MGH. The hard work put into the implementation and the subsequent quality assurance of the resulting treatment plans really gave everyone a high degree of confidence that the patient was going to get the best treatment possible," says Marc Mlyn, President of RaySearch Americas.

"The development of RayStation® has been our main focus during the last few years and I am fully convinced that it is the most advanced and modern treatment planning system on the market today. It is the vehicle that we will use to continuously bring new and improved solutions to cancer clinics all over the world to help them deliver more effective radiation therapy to their patients. Since the foundation of RaySearch more than a decade ago, software modules from our company have already been used for the treatment of millions of cancer patients. However, this is the first time that a patient was treated using a treatment plan that was completely created within RayStation®. This is of course a very important and emotional moment for us as well as the starting point of a new era for RaySearch", says Johan Löf, CEO of RaySearch.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Elekta. (2023, September 12). First clinical implementation of RayStation at MGH. News-Medical. Retrieved on November 22, 2024 from https://www.news-medical.net/news/20111003/First-clinical-implementation-of-RayStation-at-MGH.aspx.

  • MLA

    Elekta. "First clinical implementation of RayStation at MGH". News-Medical. 22 November 2024. <https://www.news-medical.net/news/20111003/First-clinical-implementation-of-RayStation-at-MGH.aspx>.

  • Chicago

    Elekta. "First clinical implementation of RayStation at MGH". News-Medical. https://www.news-medical.net/news/20111003/First-clinical-implementation-of-RayStation-at-MGH.aspx. (accessed November 22, 2024).

  • Harvard

    Elekta. 2023. First clinical implementation of RayStation at MGH. News-Medical, viewed 22 November 2024, https://www.news-medical.net/news/20111003/First-clinical-implementation-of-RayStation-at-MGH.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Elekta and the International Atomic Energy Agency (IAEA) partner to improve access to cancer care in underserved countries